Natural compound SAMe tested to block liver cancer in High-Risk patients
NCT ID NCT07495995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that predicts liver cancer risk and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- New drug miricorilant tested for fatty liver disease safety
- New drug combo targets genetic fatty liver in Mid-Stage trial
- Fatty liver study tracks 922 patients to uncover hidden risks
- DASH diet shows promise against childhood fatty liver